Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
A phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS)
Downregulation of Endogenous Peptide Production Introducing exogenous peptides may signal the body to decrease its own production of these compounds (a concept well-understood with hormonal therapies)
It helps control appetite and blood sugar levels by focusing on two hormones, GIP and GLP-1
Your clinician helps determine what is appropriate based on your health history, goals, and eligibility
US$ 29.04
US$ 27.16
US$ 25.03
US$ 29.58
